Target intelligence / Profile preview

V-type proton ATPase catalytic subunit A (ATP6V1A)

Target
ATP6V1A
Molecular classification
Enzyme, Transporter (proton pump), ATPase
01

Overview

V-type proton ATPase catalytic subunit A (ATP6V1A) is a ubiquitous enzyme subunit that forms part of the V1 domain of the vacuolar-type H+-ATPase (V-ATPase) complex. V-ATPases are responsible for the ATP-dependent acidification of intracellular organelles, which is crucial for a variety of processes including protein sorting, receptor-mediated endocytosis, synaptic vesicle loading, and lysosomal degradation. The A subunit is the catalytic core, directly involved in ATP hydrolysis, providing the energy for proton transport by the V0 domain across organelle membranes. Mutations in ATP6V1A can lead to disorders such as developmental and epileptic encephalopathy and connective tissue diseases. Pharmacological inhibition of V-ATPase, such as by bafilomycin or concanamycin, is a useful research tool but highly toxic due to the central role of ATP6V1A-containing complexes in cellular physiology[1][2][5].

Other names
ATPase H+ transporting V1 subunit AATP6A1ATP6V1A1VPP2Vma1VA68ARCL2DDEE93HO68IECEE3
02

Mechanism of action

Inhibition of proton transport by blocking ATP hydrolysis (V-ATPase inhibitors prevent acidification of intracellular compartments)

03

Biological functions

Organelle acidificationProtein sortingZymogen activationReceptor-mediated endocytosisSynaptic vesicle proton gradient generationIntracellular pH regulation
04

Disease associations

Neurodevelopmental disorders (e.g., developmental and epileptic encephalopathy 93)Connective tissue disorders (e.g., cutis laxa, autosomal recessive, type IId)Osteopetrosis (in animal and some human isoform contexts)Renal tubular acidosis (in animal and some human isoform contexts)Potentially cancer/metastasis
05

Safety considerations

Inhibition may disrupt essential organelle function including lysosomal degradation, autophagy, or neurotransmitter storageSystemic inhibition is toxic; selectivity is a challenge
06

Interacting drugs

Bafilomycin A1 (classic laboratory inhibitor, not a therapeutic drug)

1 more in the full profile.

07

Biomarkers

Acidification deficits in lysosomes (for research, not established clinical biomarker)Expression level of ATP6V1A in tissue (context specific, e.g., for research on cancer or neurodevelopmental disorders)

Beyond the preview

Go deeper on V-type proton ATPase catalytic subunit A (ATP6V1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase catalytic subunit A (ATP6V1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call